Should I buy or sell BerGenBio ASA stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BerGenBio ASA in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" BRRGF shares. View BRRGF analyst ratings or view top-rated stocks .

How have BRRGF shares performed in 2024?

BerGenBio ASA's stock was trading at $0.0250 on January 1st, 2024. Since then, BRRGF stock has increased by 0.0% and is now trading at $0.0250. View the best growth stocks for 2024 here .

How do I buy shares of BerGenBio ASA?

Shares of BRRGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:BRRGF

BerGenBio ASA (BRRGF) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free BRRGF Stock Alerts

$0.03

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.03
▼
$0.03
50-Day Range: $0.03
▼
$0.03
52-Week Range: $0.03
▼
$0.03

Volume: N/A
Average Volume: 200 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Headlines Short Interest

Get BerGenBio ASA alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About BerGenBio ASA Stock (OTCMKTS:BRRGF)

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

BRRGF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BRRGF Stock News Headlines

March 20, 2024 | finance.yahoo.com

BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation

February 7, 2024 | finance.yahoo.com

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

January 31, 2024 | lse.co.uk

Gram Car Carriers Asa Share Price (GCC.OL)

December 2, 2023 | sg.finance.yahoo.com

BerGenBio ASA (BRRGF) stock historical prices & data – Yahoo Finance

November 18, 2023 | morningstar.com

BerGenBio ASA BGBIO

November 14, 2023 | finance.yahoo.com

BerGenBio Reports Third Quarter 2023 Financial Results

November 6, 2023 | finance.yahoo.com

BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

October 31, 2023 | finance.yahoo.com

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting

October 23, 2023 | finance.yahoo.com

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

October 16, 2023 | finance.yahoo.com

Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

August 23, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on BerGenBio AS (BRRGF)

August 22, 2023 | finance.yahoo.com

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

August 15, 2023 | bbc.co.uk

Coronation concert ballot misleading, says regulator ASA

May 26, 2023 | finance.yahoo.com

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue

May 16, 2023 | markets.businessinsider.com

BerGenBio AS (BRRGF) Gets a Buy from H.C. Wainwright

April 25, 2023 | finance.yahoo.com

BerGenBio ASA: Proposed partially underwritten rights issue

March 9, 2023 | finance.yahoo.com

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

February 17, 2023 | finanznachrichten.de

BerGenBio ASA: BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

February 16, 2023 | finance.yahoo.com

BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

February 15, 2023 | finance.yahoo.com

BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

November 15, 2022 | finance.yahoo.com

BerGenBio reports third quarter 2022 financial results and provides business update

October 25, 2022 | prnewswire.com

BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS

October 11, 2022 | finance.yahoo.com

BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

September 27, 2022 | finance.yahoo.com

BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS

September 10, 2022 | reuters.com

BGBIO.OL - Bergenbio ASA | Stock Price & Latest News | Reuters

See More Headlines

Receive BRRGF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BerGenBio ASA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:BRRGF
CUSIP: N/A
CIK: N/A
Web: www.bergenbio.com
Phone: 47 53 50 15 64
Fax: N/A
Employees: 18
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Martin Olin (Age 55)
Chief Executive Officer
Comp: $880.14k
Mr. Rune Skeie (Age 51)
Chief Financial Officer
Comp: $237.76k
Ms. Gayle M. Mills M.B.A (Age 69)
Chief Business Officer
Ms. Cristina Oliva M.D.
Chief Medical Officer
Graham Morell
Head of IR
Dr. Akil Jackson
Medical Director

Key Competitors

View All Competitors

BRRGF Stock Analysis - Frequently Asked Questions

Should I buy or sell BerGenBio ASA stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BerGenBio ASA in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" BRRGF shares.
View BRRGF analyst ratings or view top-rated stocks.
How have BRRGF shares performed in 2024?: BerGenBio ASA's stock was trading at $0.0250 on January 1st, 2024. Since then, BRRGF stock has increased by 0.0% and is now trading at $0.0250.
View the best growth stocks for 2024 here.
How do I buy shares of BerGenBio ASA?: Shares of BRRGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BRRGF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial